VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Viatris, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information impacting the company's revenue outlook and growth [5][6]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $100,000 in Viatris between August 8, 2024, and February 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Viatris, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Viatris - The complaint alleges that Viatris and its executives made false and misleading statements regarding the company's financial outlook and downplayed the significance of a failed FDA inspection at its Indore facility [5]. - The lawsuit claims that the impact of the failed inspection and subsequent remediation efforts significantly affected Viatris' projected fiscal year 2025 finances, particularly regarding the manufacturing and shipping of key products like Lenalidomide [5]. Group 3: Financial Impact and Stock Performance - On February 27, 2025, Viatris announced disappointing financial results for the fourth quarter and full fiscal year 2024, attributing below-expectation guidance to the impact of the Indore facility warning letter and import alert [6]. - Following this announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, marking a decline of approximately 15.21% in one day [7].